We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Global Digital PCR and Real-Time PCR Market Growth Driven by Increasing Cases of Infectious Diseases

By LabMedica International staff writers
Posted on 20 Apr 2021
Increasing cases of infectious diseases, rising geriatric population and growing number of genetic disorders will propel the growth of the global digital PCR and real-time PCR market over the next decade. More...
Additionally, PCR advances, fulfillment of the human genome project, and expanding R&D will increase the utilization of biomarker profiling for sickness diagnostics, thus further driving market growth.

These are the latest findings of TMR Research (San Francisco, CA, USA), a provider of customized market research and consulting services.

The interest in genomic examination strategies has increased consistently during the most recent decade due to their expanding use in the analysis of major illnesses (like HIV, tuberculosis, intestinal sickness, and hepatitis) and hereditary problems (like malignancy). The development in the commonness of target illnesses worldwide, combined with the demonstrated adequacy of qPCR and dPCR examination in the determination and assessment of sickness-causing microorganisms, will drive the utilization of clinical indicative tests (including qPCR and dPCR investigation) and support market development.

Geographically, North America is expected to dominate the global digital PCR and real-time PCR market, followed by Europe. The development of the North American qPCR and dPCR market will be driven by an expanded selection of innovative and novel genomic examination items (including progressed qPCR and dPCR items), accessibility to R&D financing for genomic research, growing utilization of PCR methods in clinical diagnostics and criminology, and early commercialization of qPCR/dPCR items.

Related Links:
TMR Research


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hybrid Pipette
SWITCH
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Cancer-specific small RNAs released into blood act as molecular barcodes that reveal tumor identity (Photo courtesy of Arc Institute)

Blood Test Could Detect Molecular Barcodes Capable of Distinguishing Cancer Types

Some cancers are difficult to classify, track, and monitor after treatment, posing a major clinical challenge. Many tumors shed little DNA into the bloodstream, making it hard to detect minimal residual... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.